HPTN 083

#GivePrEPaSHOT

Raphael J. Landovitz, MD MSc
UCLA Center for Clinical AIDS Research & Education
Los Angeles, CA, USA
April 11, 2017
Study Rationale

- Daily oral TDF/FTC is highly effective when taken as prescribed
- Some individuals find it challenging to take oral tablets daily
- CAB is an investigational integrase inhibitor being developed for
  - HIV treatment (in combination with other ARVs)
  - HIV prevention (alone, as a single drug)
- CAB is available both as a daily pill and as a long-acting intramuscular injection given every 1-2 months
Study Design and Duration

• Randomized, double-blind active-controlled comparison of daily oral TDF/FTC and injectable CAB
  – 5 week oral “lead in” – 2 tablets daily
  – ~3.5 year injectable phase – injections + daily tablets
  – 1 year “open-label phase” – everyone receives HIV prevention package + daily oral TDF/FTC
Study Population and Size

- >18 yo, HIV-uninfected, increased risk MSM and TGW
- 4500 participants
  - 45 sites in 8 countries
  - >50% under age 30
  - >50% of US enrollment BMSM
  - >10% TGW
Efficacy of injectable CAB compared to daily oral TDF/FTC for HIV prevention
Safety of injectable CAB compared to daily oral TDF/FTC
Acceptability and preferences for injectable vs. oral PrEP
Compare rates and types of drug resistance in people who acquire HIV after taking TDF/FTC or CAB
Clinical Research Sites

45 sites in 8 Countries
Current Study Status

- Open to enrollment December, 2016
- First enrollment: December 19, 2016
- Sites Activated:
  - US:
  - Non-US:
- Currently Enrollment
- Estimated Completion of Enrollment:
- Estimated Results Available: 2021
Community Engagement

- Initial concept review, inclusion/exclusion criteria review, science review
- Community preparedness meetings (regionally focused)
- Central resource development
- Site CEWP development/review
- CPM 6 meetings with protocol team; 2 community workshops
- Cultural responsiveness training (PAT)
- 6 national/international external stakeholder events at scientific meetings
ACKNOWLEDGEMENTS

The HIV Prevention Trials Network is sponsored by the National Institute of Allergy and Infectious Diseases, the National Institute of Mental Health, and the National Institute on Drug Abuse, all components of the U.S. National Institutes of Health.